Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

AbCellera and Eli Lilly present second antibody to enter clinical development against COVID-19

May 6, 2021

Ascletis reports phase IIa data on ASC-22 for chronic hepatitis B

May 5, 2021

First healthy volunteers dosed in phase I/II study of HDT Bio's COVID-19 RNA vaccine in India

May 5, 2021

Vaxart initiates enrollment in phase Ib boosting regimen trial of its norovirus vaccine

May 5, 2021

Mitochondrial peptide causes septic shock nosocomials, mortality

May 4, 2021

Ongoing TOGETHER platform study will evaluate Lambda in outpatients with COVID-19

May 4, 2021

Synairgen reports home cohort and combined analysis from phase II trial of SNG-001 in COVID-19

May 3, 2021

U.S. researchers discover new CARs against cytomegalovirus

May 3, 2021

Preclinical through phase III, new COVID-19 therapy trials ramp up

April 30, 2021

Phase II trial of vonoprazan regimens for H. pylori infection meets endpoints

April 30, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...